-
BetterLife Engages Canadian Healthcare Investment Firm, Aims For Clinical Trial Programs
Thursday, January 26, 2023 - 2:02pm | 372Read More...BetterLife Pharma (OTCQB: BETRF), a non-hallucinogenic psychedelics biotech company, has contracted Bloom Burton Securities Inc. for strategic advisory services. “Canada’s leading healthcare investment banking firm” holds “extensive understanding” of the overall...
-
UPDATE: Bloom Burton Downgrades YM BioSciences to Hold Post Gilead Acquisition
Monday, December 17, 2012 - 2:10pm | 125Read More...Bloom Burton lowered its rating on YM BioSciences (NYSE: YMI) from Buy to Hold with a $2.95 price target. Bloom Burton noted, "We are updating our price target to US$2.95 and rating to Hold after last week's announcement of the acquisition of YM by Gilead Sciences (NASDAQ: GILD). … The deal is...
-
UPDATE: Bloom Burton Cuts PT to $24 on OncoGenex Pharmaceuticals
Friday, March 9, 2012 - 1:24pm | 65Read More...Bloom Burton lowers its price target on BUy-rated OncoGenex Pharmaceuticals (NASDAQ: OGXI to $24 as the timing of Custirsen approval is pushed back Bloom Burton notes, "Price target decreased to $24.00 from $28.00. This is mainly due to pushing back our timing of custirsen approval for second-...
